Inhibition of the renin-angiotensin system and target organ protection

Hypertension Research

Volumn 32, Issue 4, 2009, Pages 229-237

  Iwanami, Jun ^a   Mogi, Masaki ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibroproliferative disease; Inflammation; Local RAS; Organ damage; Oxidative stress

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CARDIOTONIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; EPROSARTAN; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRENDIPINE; OLMESARTAN; PLACEBO; SPIRONOLACTONE; TRANSCRIPTION FACTOR ETS 1; UNINDEXED DRUG; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE ACTIVITY; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BRAIN PROTECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; PRIMARY PREVENTION; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; BLOOD VESSELS; BRAIN; HUMANS; HYPERTENSION; KIDNEY; METABOLIC SYNDROME X; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM;

EID: 68849130125     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.5     Document Type: Review

References (133)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data, Lancet 2005; 365: 217-223. (Pubitemid 40138015)
2. Chobanlan AV, Bakrls GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparll S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA 2003; 289: 2560-2572.
3. Dzau V, Braunwald E. Resolved and unresolved issues In the prevention and treatment of coronary artery disease: a workshop consensus statement, Am Heart J 1991; 121: 1244-1263.
4. de Gasparo M, Catt KJ. Inagami T. Wright JW, Unger T. International Union of Pharmacology, XXIII, The angiotensin II receptors, Pharmacol Rev 2000; 52: 415-472.
5. Shivakumar BR, Wang Z, Hammond TG, Harris RC, EP24.15 interacts with the angiotensin II type I receptor and bradykinln B2 receptor, Cell Biochem Funct 2005; 23: 195-204. (Pubitemid 40695404)
6. Seachrist JL, Laporte SA, Dale LB, Babwah AV, Caron MG, Anborgh PH, Ferguson SS, Rab5 association with the angiotensin II type 1A receptor promotes Rab5GTP binding and vesicular fusion, J Biol Chem 2002; 277: 679-685.
7. Scott MG, Pierottl V, Storez H, Lindberg E, Thuret A, Muntaner O, Labbé-Julllé C, Pitcher JA, Marullo S, Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by fllamln A and beta-arrestlns, Mol Cell Biol 2006; 26: 3432-3445.
8. Pulakat L, Gray A, Johnson J, Knowle D, Burns V, Gavini N, Role of C-terminal cytoplasmic domain of the AT2 receptor in ligand binding and signaling, FEBS Lett 2002; 524: 73-78. (Pubitemid 34804837)
9. Pulakat L, Cooper S, Knowle D, Mandavla C, Bruhl S, Hetrlck M, Gavinl N, Liganddependent complex formation between the angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 In mammalian cells, Peptides 2005; 26: 863-873. (Pubitemid 40461668)
10. Fessart D, Simaan M, Laporte SA, c-Src regulates clathrin adapter protein 2 interaction with beta-arrestln and the angiotensin II type 1 receptor during clathrin-medlated Internalization, Mol Endocrinol 2005; 19: 491-503. (Pubitemid 40223471)
11. Daviet L, Lehtonen JY, Tamura K, Griese DP, Horluchi M, Dzau VJ, Cloning and characterization of ATRAP, a novel protein that Interacts with the angiotensin II type 1 receptor, J Biol Chem 1999; 274: 17058-17062. (Pubitemid 129519035)
12. Nouet S, Amzallag N, LI JM, Louis S, Seltz I, Cui TX, Alleaume AM, Dl Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmlas C. TransInactivatlon of receptor tyrosine kinases by novel angiotensin II AT2 receptor-Interacting protein, ATIP, J Biol Chem 2004; 279: 28989-28997. (Pubitemid 38915768)
13. Lopez-llasaca M, Liu X, Tamura K, Dzau VJ, The angiotensin II type I receptorassociated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling, Mol Biol Cell 2003; 14: 5038-5050. (Pubitemid 37484817)
14. Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Tamura K, Daviet L, Horiuchi M, ATRAP, novel AT1 receptor associated protein, enhances Internalization of AT1 receptor and inhibits vascular smooth muscle cell growth, Biochem Biophys Res Commun 2000; 279: 938-941. (Pubitemid 32042880)
15. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U, The angiotensin II AT2 receptor is an AT1 receptor antagonist, J Biol Chem 2001; 276: 39721-39726.
16. AbdAlla S, Lother H, Quitterer U, AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration, Nature 2000; 407: 94-98.
17. Ollvares-Reyes JA, Shah BH, Hernandez-Aranda J, García-Caballero A, Farshorl MP, García-Sálnz JA, Catt KJ, Agonist-Induced interactions between angiotensin AT1 and epidermal growth factor receptors, Mol Pharmacol 2005; 68: 356-364. (Pubitemid 41058299)
18. Zeng C, Asico LD, Wang X, Hopfer U, Eisner GM, Felder RA, Jose PA, Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR, Hypertension 2003; 41: 724-729. (Pubitemid 36314582)
19. Zeng C, LIu Y, Wang Z, He D, Huang L, Yu P, Zheng S, Jones JE, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA, Activation of D3 dopamine receptor decreases angiotensin Il type 1 receptor expression In rat renal proximal tubule cells, Circ Res 2006; 99: 494-500. (Pubitemid 44337821)
20. Zeng C, Luo Y, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA, Perturbation of Dl dopamine and ATI receptor interaction in spontaneously hypertensive rats, Hypertension 2003; 42: 787-792. (Pubitemid 37237326)
21. Zeng C, Yang Z, Wang Z, Jones J, Wang X, Altea J, Mangrum AJ, Hopfer U, Sibley DR, Eisner GM, Felder RA, Jose PA, Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells, Hypertension 2005; 45: 804-810. (Pubitemid 40418385)
22. Zeng C, Wang Z, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA, Aberrant ETB receptor regulation of AT receptors In immortalized renal proximal tubule cells of spontaneously hypertensive rats, Kidney Int 2005; 68: 623-631. (Pubitemid 43323117)
23. Von Bohlen und Halbach O, Walther T, Bader M, Albrecht D, Interaction between Mas and the angiotensin ATI receptor in the amygdala, J Neurophysiol 2000; 83: 2012-2021. (Pubitemid 30198656)
24. Bond RA, Ijzerman AP, Recent developments In constitutive receptor activity and inverse agonlsm, and their potential for GPCR drug discovery, Trends Pharmacol Sci 2006; 27: 92-96.
25. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Mlnamino T, Maklta N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagal T, Fukamizu A, Umemura S, Iiri T, Fujlta T, Komuro I, Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II, Nat Cell Biol 2004; 6: 499-506. (Pubitemid 38786592)
26. Komuro I, New mechanism of heart protection by angiotensin receptor blockers, Drugs Today (Barc) 2006; 42(Suppl C): 25-28. (Pubitemid 46145178)
27. Wallukat G, Homuth V, Fischer T, Llndschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC, Patients with preeclampsia develop agonistic autoantibodies against the angiotensin ATI receptor, J Clin Invest 1999; 103: 945-952. (Pubitemid 29169601)
28. Dragun D, Brasen JH, Schonemann C, Frltsche L, Budde K, Neumayer HH, Luft FC, Wallukat G, Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor, Transplant Proc 2003; 35: 2104-2105. (Pubitemid 37194332)
29. Dragun D, Muller DN, Brasen JH, Frltsche L, Niemlnen-Kelhä M, Dechend R, Klntscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G, Angiotensin II type 1-receptor activating antibodies In renal-allograft rejection, W Engl J Med 2005; 352: 558-569. (Pubitemid 40204669)
30. Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J MoI Med 2008; 86: 685-690.
31. Reaux A, Fournle-Zaluskl MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001; 12: 157-162.
32. Nagata S. Kato J, Sasaki K, Mlnamino N, Eto T, Kitamura K, Isolation and Identification of proanglotensin-12, a possible component of the renin-angiotensin system, Biochem Biophys Res Commun 2006; 350: 1026-1031. (Pubitemid 44596223)
33. Min LJ, Mogl M. Li JM, Iwanaml J, Iwai M, Horluchi M, Aldosterone and angiotensin II synergistlcally Induce mitogenlc response in vascular smooth muscle cells, Circ Res 2005; 97: 434-442. (Pubitemid 41298173)
34. Min LJ, Mogi M, Iwanaml J. Li JM, Sakata A, Fujlta T, Tsukuda K, Iwai M, Horluchi M, Cross-talk between aldosterone and angiotensin Il In vascular smooth muscle cell senescence, Cardiovase Res 2007; 76: 506-516. (Pubitemid 350007454)
35. Suzuki H, Motley ED, Frank GD, Utsunomlya H, Eguchi S. Recent progress In signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 305-322. (Pubitemid 41264268)
36. Hilgers KF, Hilgenfeldt U, Veelken R, Muley T, Ganten D, Luft FC, Mann JF. Angiotensinogen is cleaved to angiotensin in isolated rat blood vessels. Hypertension 1993; 21: 1030-1034. (Pubitemid 23166962)
37. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, Sowers JR. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391. (Pubitemid 47205789)
38. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148. (Pubitemid 24176909)
39. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers IV Q, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51. (Pubitemid 27030367)
40. Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 2002; 362: 733-739. (Pubitemid 34242326)
41. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006; 25: 6731-6748. (Pubitemid 44657849)
42. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res 2007; 101: 985-994. (Pubitemid 350084976)
43. Adachi T, Yamamoto M, Suematsu M. Targeting NAD(P)H oxidase: Ets-1 regulates p47(phox). Circ Res 2007; 101: 962-964.
44. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-2183.
45. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007; 27: 2576-2581.
46. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 1997; 236: 622-625. (Pubitemid 27384676)
47. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-587. (Pubitemid 30012061)
48. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005; 93: 1069-1076. (Pubitemid 40823510)
49. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconvertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
50. Kunieda T, Minamino T, Nishi J, Tateno K, Oyama T, Katsuno T, Miyauchi H, Orimo M, Okada S, Takamura M, Nagai T, Kaneko S, Komuro I. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006; 114: 953-960. (Pubitemid 44337139)
51. de Cavanagh EM, Piotrkowski B, Fraga CG. Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med 2004; 25: 27-36. (Pubitemid 38401929)
52. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128: 247-252. (Pubitemid 40544840)
53. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M. Longterm oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985; 71: 963-971. (Pubitemid 15035247)
54. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677-683. (Pubitemid 19072485)
55. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990; 82: 774-780.
56. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.N Engl JMed 1991; 325: 1468-1475.
57. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231. (Pubitemid 26290520)
58. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99: 1265-1270.
59. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. Am J Cardiol 1992; 69: 103-107.
60. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-691.
61. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. (Pubitemid 33126822)
62. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
63. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuss M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995; 91: 1461-1471.
64. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95: 1201-1206.
65. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeyer T, Perryman MB, Bristow MR. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 1998; 98: 1735-1741. (Pubitemid 28492493)
66. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100: 2093-2099. (Pubitemid 29532061)
67. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97: 931-936. (Pubitemid 30070412)
68. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34. (Pubitemid 30127593)
69. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Yazaki Y. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 1996; 271: 33592-33597. (Pubitemid 27010177)
70. Yamazaki T, Komuro I, Shiojima I, Yazaki Y. Angiotensin II mediates mechanical stress-induced cardiac hypertrophy. Diabetes Res Clin Pract 1996; 30(Suppl): 107-111. (Pubitemid 126352584)
71. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571. (Pubitemid 27142455)
72. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
73. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
74. van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317.
75. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16: 703-711. (Pubitemid 41725107)
76. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
77. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-259. (Pubitemid 30429870)
78. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25. (Pubitemid 39274273)
79. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 32927514)
80. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
81. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
82. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-919. (Pubitemid 44634312)
83. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458. (Pubitemid 28124757)
84. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
85. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465. (Pubitemid 12203819)
86. Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148. (Pubitemid 44297536)
87. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
88. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
89. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-1703.
90. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843-848. (Pubitemid 39096013)
91. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003; 17: 2094-2096.
92. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U, Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619. (Pubitemid 40471263)
93. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615-1626. (Pubitemid 30650600)
94. Cote F, Laflamme L, Payet MD, Gallo-Payet N. Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-15 cells. Endocr Res 1998; 24: 403-407. (Pubitemid 29016414)
95. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686-31692.
96. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007; 566: 153-159. (Pubitemid 46782806)
97. Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 2007; 73: 198-205.
98. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-449.
99. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50: 1099-1105. (Pubitemid 350172932)
100. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402. (Pubitemid 350096995)
101. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863-47868. (Pubitemid 37370682)
102. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686692.
103. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
104. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
105. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611. (Pubitemid 35278594)
106. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707. (Pubitemid 34564280)
107. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982. (Pubitemid 39336681)
108. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006; 48: 1095-1102. (Pubitemid 44772713)
109. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010. (Pubitemid 38579905)
110. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999; 161: 317-322. (Pubitemid 29244259)
111. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248. (Pubitemid 38315360)
112. Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, Nakazawa T, Ohara H, Nomura T, Joh T, Shirai T, Itoh M. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003; 124: 1010-1019. (Pubitemid 36389804)
113. Yamada T, Kuno A, Masuda K, Ogawa K, Sogawa M, Nakamura S, Ando T, Sano H, Nakazawa T, Ohara H, Nomura T, Joh T, Itoh M. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J Pharmacol Exp Ther 2003; 307: 17-23. (Pubitemid 37151887)
114. Daniel C. Blocking of angiotensin II is more than blocking of transforming growth factor-beta. Kidney Int 2008; 74: 551-553.
115. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667-1676. (Pubitemid 35231666)
116. Morris BJ, Iwamoto HS, Reid IA. Localization of angiotensinogen in rat liver by immunocytochemistry. Endocrinology 1979; 105: 796-800. (Pubitemid 9257473)
117. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112: 1383-1394. (Pubitemid 38057692)
118. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun 2003; 308: 177-183.
119. Yang L, Bataller R, Dulyx J, Coffman TM, Gine's P, Rippe RA, Brenner DA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005; 43: 317-323.
120. Yoshiji H, Noguchi R, Fukui H. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 215-216. (Pubitemid 40425214)
121. Wei YH, Jun L, Qiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci 2004; 49: 1589-1594. (Pubitemid 39335540)
122. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M, Chayama K. Antifibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem Biophys Res Commun 2006; 346: 658-664. (Pubitemid 43913673)
123. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139: 1085-1094. (Pubitemid 36920670)
124. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med 1975; 59: 365-372.
125. Specks U, Martin II WJ, Rohrbach MS. Bronchoalveolar lavage fluid angiotensinconverting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990; 141: 117-123. (Pubitemid 20023393)
126. Fourrier F, Chopin C, Wallaert B, Mazurier C, Mangalaboyi J, Durocher A. Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. Chest 1985; 87: 191-195. (Pubitemid 15174050)
127. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol 2001; 32: 521-528.
128. Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007; 13: 1247-1256. (Pubitemid 46739332)
129. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
130. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz III HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358: 2787-2795. (Pubitemid 351930853)
131. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210.
132. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm Jr RH, Messerli FH, Oparil S, Schork MA, Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med 2006; 354: 1685-1697.
133. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.